Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-875 (Fasiglifam) add-on to glimepiride in type 2 diabetes mellitus
2013-000007-17Phase 3Terminated
- Sponsor
- Takeda
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing TAK-875 50 mg + glimepiride with Placebo + glimepiride (2 arms). Primary endpoint: Change from baseline in HbA1c at Week 24. Started May 2013; status: terminated.
02
Drugs
fasiglifam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-000007-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000007-17.